Ocular Therapeutix Inc (OCUL)

Apr 05, 2026

Here is why Ocular Therapeutix (OCUL) is highly favored by hedge funds - MSN

Apr 05, 2026

Apr 03, 2026

Behavioral Patterns of OCUL and Institutional Flows - Stock Traders Daily

Apr 03, 2026

Apr 02, 2026

OCULAR THERAPEUTIX, INC. (OCUL) - MSN

Apr 02, 2026

Apr 02, 2026

HC Wainwright lifts Ocular Therapeutix, Inc. (OCUL) price target following intravitreal implant FDA submission - MSN

Apr 02, 2026

Apr 02, 2026

OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill

Apr 02, 2026

Apr 02, 2026

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April - Sahm

Apr 02, 2026

Apr 01, 2026

Analysis Recap: How sensitive is Ocular Therapeutix Inc to inflation2026 Analyst Calls & Daily Technical Stock Forecast Reports - baoquankhu1.vn

Apr 01, 2026

Apr 01, 2026

OCUL Earning Date, Earning Analysis and Earning Prediction - intellectia.ai

Apr 01, 2026

Apr 01, 2026

Ocular lines up April talks on wet AMD trial data and retinal disease - Stock Titan

Apr 01, 2026

Apr 01, 2026

Here is Why Ocular Therapeutix (OCUL) is Highly Favored by Hedge Funds - Insider Monkey

Apr 01, 2026

Mar 31, 2026

Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $31 - Moomoo

Mar 31, 2026

Mar 31, 2026

Ocular Therapeutix (NASDAQ:OCUL) Shares Up 9.3%Should You Buy? - marketbeat.com

Mar 31, 2026

Mar 30, 2026

OCULAR THERAPEUTIX (01477.HK) Completes First Patient Enrollment in Phase III Clinical Trial for OT-211 - AASTOCKS.com

Mar 30, 2026

Mar 29, 2026

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Short Interest Up 34.2% in March - MarketBeat

Mar 29, 2026

Mar 29, 2026

Assenagon Asset Management S.A. Has $7.54 Million Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat

Mar 29, 2026

Mar 28, 2026

Why Ocular Therapeutix (OCUL) Is Down 7.7% After Single‑Trial FDA Plan For AXPAXLI Superiority Claim - Sahm

Mar 28, 2026

Mar 27, 2026

What Ocular Therapeutix (OCUL)'s Single-Study FDA Bid After SOL-1 Superiority Means For Shareholders - Yahoo Finance

Mar 27, 2026

Mar 27, 2026

Vanguard reports zero holdings in Ocular Therapeutix (OCUL) - Stock Titan

Mar 27, 2026

Mar 27, 2026

H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy - Investing.com

Mar 27, 2026

Mar 27, 2026

H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy By Investing.com - Investing.com UK

Mar 27, 2026

Mar 27, 2026

H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $21 - Moomoo

Mar 27, 2026

Mar 26, 2026

Ocular Therapeutix, Inc. (OCUL): A bull case theory - MSN

Mar 26, 2026

Mar 25, 2026

Ocular Therapeutix Touts Landmark Phase 3 AXPAXLI Win at RBC Ophthalmology Conference - marketbeat.com

Mar 25, 2026

Mar 25, 2026

Ocular Therapeutix at RBC Conference: Promising AXPAXLI Data By Investing.com - Investing.com Canada

Mar 25, 2026

Mar 25, 2026

OCUL: AXPAXLI showed phase III superiority over anti-VEGF, with strong regulatory and clinical momentum - TradingView

Mar 25, 2026

Mar 25, 2026

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com

Mar 25, 2026

Mar 24, 2026

Citizens reiterates Ocular Therapeutix stock rating amid litigation By Investing.com - Investing.com Canada

Mar 24, 2026

Mar 24, 2026

Citizens reiterates Ocular Therapeutix stock rating amid litigation - Investing.com

Mar 24, 2026

Mar 23, 2026

Jeffrey S. Heier, MD, Chief Scientific Officer, Ocular Therapeutix - healio.com

Mar 23, 2026

Mar 23, 2026

EyePoint lawsuit accuses Ocular of 'malicious' defamation campaign in retina drug race - Fierce Pharma

Mar 23, 2026

Mar 22, 2026

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug - Reuters

Mar 22, 2026

Mar 21, 2026

EyePoint sues Ocular over claims related to lead asset - MSN

Mar 21, 2026

Mar 21, 2026

EyePoint (EYPT) Sues Ocular Therapeutix (OCUL) Over False Claims - GuruFocus

Mar 21, 2026

Mar 21, 2026

EyePoint files a lawsuit against Ocular (EYPT:NASDAQ) - Seeking Alpha

Mar 21, 2026

Mar 21, 2026

EyePoint, Inc. Files Complaint Against Ocular Therapeutix—Key Details from Latest 8-K SEC Filing - Minichart

Mar 21, 2026

Mar 20, 2026

On March 20, 2026, EyePoint has officially filed a lawsuit against biotechnology company Ocular Therapeutix in the Superior Court of Middlesex County, Massachusetts, USA. - Bitget

Mar 20, 2026

Mar 20, 2026

EyePoint Sues Ocular Therapeutix Over Alleged Defamation - TipRanks

Mar 20, 2026

Mar 19, 2026

Cantor Fitzgerald L. P. Buys Shares of 201,865 Ocular Therapeutix, Inc. $OCUL - MarketBeat

Mar 19, 2026

Mar 18, 2026

VR Adviser Reduces Ocular Therapeutix Stake in Q4 2025 | Portfolio ImpactNews and Statistics - IndexBox

Mar 18, 2026

Mar 18, 2026

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down - AOL.com

Mar 18, 2026

Mar 18, 2026

Is It Time To Reassess Ocular Therapeutix (OCUL) After Its Recent Share Price Slide - Yahoo Finance

Mar 18, 2026

Mar 17, 2026

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Short Interest Up 20.0% in February - MarketBeat

Mar 17, 2026

Mar 17, 2026

Ocular Therapeutix Stock & Financial Performance Review 2026News and Statistics - IndexBox

Mar 17, 2026

Mar 17, 2026

3 Reasons to Avoid OCUL and 1 Stock to Buy Instead - Yahoo Finance

Mar 17, 2026

Mar 16, 2026

A Look At Ocular Therapeutix (OCUL) Valuation After Recent Share Price Weakness - simplywall.st

Mar 16, 2026

Mar 15, 2026

Ocular Therapeutix Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo

Mar 15, 2026